Free Trial
NASDAQ:DXCM

DexCom (DXCM) Stock Price, News & Analysis

DexCom logo
$80.04 +4.22 (+5.57%)
(As of 12/20/2024 05:45 PM ET)

About DexCom Stock (NASDAQ:DXCM)

Key Stats

Today's Range
$75.47
$81.51
50-Day Range
$67.10
$81.01
52-Week Range
$62.34
$142.00
Volume
11.49 million shs
Average Volume
3.91 million shs
Market Capitalization
$31.26 billion
P/E Ratio
47.93
Dividend Yield
N/A
Price Target
$98.00
Consensus Rating
Moderate Buy

Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
98th Percentile Overall Score

DXCM MarketRank™: 

DexCom scored higher than 98% of companies evaluated by MarketBeat, and ranked 27th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.72, and is based on 11 buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    DexCom has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about DexCom's stock forecast and price target.
  • Earnings Growth

    Earnings for DexCom are expected to grow by 18.71% in the coming year, from $1.71 to $2.03 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DexCom is 47.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.79.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DexCom is 47.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.11.

  • Price to Earnings Growth Ratio

    DexCom has a PEG Ratio of 2.46. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    DexCom has a P/B Ratio of 14.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.16% of the outstanding shares of DexCom have been sold short.
  • Short Interest Ratio / Days to Cover

    DexCom has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in DexCom has recently decreased by 7.68%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    DexCom does not currently pay a dividend.

  • Dividend Growth

    DexCom does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.16% of the outstanding shares of DexCom have been sold short.
  • Short Interest Ratio / Days to Cover

    DexCom has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in DexCom has recently decreased by 7.68%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    DexCom has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for DexCom this week, compared to 21 articles on an average week.
  • Search Interest

    Only 12 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.
  • MarketBeat Follows

    Only 13 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is a decrease of -35% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $318,275.00 in company stock.

  • Percentage Held by Insiders

    Only 0.30% of the stock of DexCom is held by insiders.

  • Percentage Held by Institutions

    97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about DexCom's insider trading history.
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

DXCM Stock News Headlines

DexCom, Inc. (NASDAQ:DXCM) EVP Sells $318,275.07 in Stock
Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
Early notable gainers among liquid option names on December 20th
RBC Capital Sticks to Its Buy Rating for Dexcom (DXCM)
See More Headlines

DXCM Stock Analysis - Frequently Asked Questions

DexCom's stock was trading at $124.09 at the start of the year. Since then, DXCM stock has decreased by 35.5% and is now trading at $80.04.
View the best growth stocks for 2024 here
.

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings results on Thursday, July, 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.04. The company's revenue for the quarter was up 15.3% on a year-over-year basis.
Read the conference call transcript
.

DexCom's stock split before market open on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly minted shares were payable to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

DexCom subsidiaries include TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and more.

DexCom's top institutional investors include Baillie Gifford & Co. (3.84%), Geode Capital Management LLC (2.54%), Jennison Associates LLC (1.77%) and Groupama Asset Managment (0.73%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Steven Robert Pacelli, Jereme M Sylvain, Sadie Stern, Michael Jon Brown, Barry J Regan, Steven R Altman, Paul R Flynn, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Bridgette P Heller, Chad Patterson and Barbara Kahn.
View institutional ownership trends
.

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Invesco QQQ (QQQ).

Company Calendar

Last Earnings
7/25/2024
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:DXCM
CUSIP
25213110
Employees
9,600
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$98.00
High Stock Price Target
$130.00
Low Stock Price Target
$75.00
Potential Upside/Downside
+22.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.72
Research Coverage
18 Analysts

Profitability

Net Income
$541.50 million
Pretax Margin
18.81%

Debt

Sales & Book Value

Annual Sales
$3.95 billion
Cash Flow
$2.06 per share
Book Value
$5.35 per share

Miscellaneous

Free Float
389,423,000
Market Cap
$31.26 billion
Optionable
Optionable
Beta
1.12

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:DXCM) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners